Genital herpes
Therapeutic area
Infectious Disease
Rare disease
No
- Definition
- Herpes simplex infection of the genitals, most commonly caused by the herpes simplex-2 virus.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Genital herpes
- Therapeutic area
- Infectious Disease
- genital herpes
- herpes genitalia
- herpes genitalis
- Disease mechanisms
- Acquired
- Severity
- Moderate
- Infectious Disease
- Reproductive Health
- MONDO ID
- MONDO:0005770
- Parent condition
- MONDO:0004609
Related records
Broader conditions (14)
- Disease
- Disease arising from reactivation of latent virus
- Disease by body system or component
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Herpes simplex infectious disease
- Herpesviridae infectious disease
- Human disease
- Infectious disease
- Primary viral infectious disease
- Reproductive system disorder
- Sexually transmitted disease
- Viral infectious disease
- Viral sexually transmitted disease
Narrower conditions (2)
- Genital herpes simplex type 1 infectious disorder
- Genital herpes simplex type 2 infectious disorder
Trials (69)
- A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected Persons
- A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients
- A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621
- A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) Post-Vaccination
- A Randomized Trial to Evaluated the Suppressive Effect of Acyclovir on Rapidly Cleared HSV-2 Reactivation
- A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
- A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes
- A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes
- A Study of the Characteristics of Patients Diagnosed With Recurrent Symptomatic Genital Herpetic Disease
- A Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected Patients
- A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes
- A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-5366 in Healthy Participants and Participants Seropositive for HSV-2 With Recurrent Genital Herpes
- A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes
- A Study to Compare the Efficacy and Safety of Valacyclovir Hydrochloride ( 256U87 ) Versus Acyclovir in the Treatment of Recurrent Anogenital Herpes Infections in HIV Infected Patients
- A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding
- A Study to Investigate the Efficacy, Safety and Tolerability of PEG in Patients With Genital Herpes
- A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
- Acyclovir to Treat Patients Co-infected With HIV and Herpes Viruses in Uganda
- An Epidemiological Study to Assess Performance of Using Healthcare Tools to Understand Genital Herpes Simplex Virus-2 (HSV-2) in Patients ≥ 18 Years of Age in the United States and Europe.
- Anti-Herpetic Treatment of Genital Ulcer : Effect on HIV & Herpes Shedding (ANRS 1212)
Approved drugs (5)
- Acyclovir
- Acyclovir sodium
- Famciclovir
- Valacyclovir
- Valacyclovir hydrochloride
Drugs in development (5)
- Amenamevir Phase 2
- Astodrimer Phase 1
- Astodrimer sodium Phase 1
- Pritelivir Phase 2
- Sodium chloride Phase 2